Evidence map›Paper›PMID 33758859›Full record

ArticlebioRxiv : the preprint server for biology2021

Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical COVID-19 correlate with poor ISG response and upregulation of LAIR1 surface protein in PBMCs.

Monique G P van der Wijst, Sara E Vazquez, George C Hartoularos, Paul Bastard, Tianna Grant, Raymund Bueno, David S Lee, John R Greenland, Yang Sun, Richard Perez and 36 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 29 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 12 institutions in 4 countries.

Monique G P van der WijstDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Sara E VazquezMedical Scientist Training Program, University of California. San Francisco, CA, USA.
George C HartoularosInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Paul BastardLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
Tianna GrantInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Raymund BuenoInstitute of Human Genetics, University of California, San Francisco, CA, USA.
David S LeeInstitute of Human Genetics, University of California, San Francisco, CA, USA.
John R GreenlandDepartment of Medicine, San Francisco VA Health Care System, University of California, San Francisco, CA, USA.
Yang SunInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Richard PerezInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Anton OgorodnikovInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Alyssa WardInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Sabrina A MannDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
Kara L LynchZuckerberg San Francisco General, San Francisco, CA, USA.
Cassandra YunZuckerberg San Francisco General, San Francisco, CA, USA.
Diane V HavlirDivision of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Gabriel ChamieDivision of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Carina MarquezDivision of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Bryan GreenhouseDivision of HIV, Infectious Disease and Global Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Michail S LionakisLaboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Philip J NorrisZuckerberg San Francisco General, San Francisco, CA, USA.
Larry J DumontVitalant Research Institute, Denver, CO, USA.
Kathleen KellyVitalant Research Institute, Denver, CO, USA.
Peng ZhangSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Qian ZhangSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Adrian GervaisUniversity of Paris, Imagine Institute, Paris, France.
Tom Le VoyerUniversity of Paris, Imagine Institute, Paris, France.
Alexander WhatleyDepartment of Electrical Engineering and Computer Sciences, University of California, Berkeley, CA, USA.
Yichen SiDepartment of Biostaticstics, University of Michigan.
Ashley ByrneChan Zuckerberg Biohub, San Francisco, CA, USA.
Alexis J CombesImmunoX Initiative, University of California, San Francisco, CA, USA.
Arjun Arkal RaoImmunoX Initiative, University of California, San Francisco, CA, USA.
Yun S SongChan Zuckerberg Biohub, San Francisco, CA, USA.
UCSF COMET consortium
Gabriela K FragiadakisDivision of Rheumatology, Department of Medicine, University of California, San Francisco, California, USA.
Kirsten KangelarisDivision of Infectious Disease, Department of Medicine, University of California, San Francisco, CA, USA.
Carolyn S CalfeeDivision of Pulmonary and Critical Care Medicine, Department of Medicine and the Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
David J ErleInstitute of Human Genetics, University of California, San Francisco, CA, USA.
Carolyn HendricksonDivision of Pulmonary and Critical Care Medicine, Department of Medicine and the Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
Matthew F KrummelImmunoX Initiative, University of California, San Francisco, CA, USA.
Prescott G WoodruffImmunoX Initiative, University of California, San Francisco, CA, USA.
Charles R LangelierDivision of Infectious Disease, Department of Medicine, University of California, San Francisco, CA, USA.
Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
Joseph L DerisiDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
Mark S AndersonDiabetes Center, University of California, San Francisco, CA, USA.
Chun Jimmie YeInstitute of Human Genetics, University of California, San Francisco, CA, USA.
University of California, San Francisco · USChan Zuckerberg Initiative (United States) · USRockefeller University · USUniversité Paris Cité · FRDartmouth College · USHoward Hughes Medical Institute · USInserm · FRNational Institutes of Health · USUniversity Medical Center Groningen · NLUniversity of California, Berkeley · USUniversity of Michigan · USVitalant · US

Funding

Understanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nirav Rati Bhakta · 2008 to 2026
$41.1M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
Yale Center for Mendelian GenomicsUM1HG006504 · NHGRI · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER, GUNEL, MURAT · 2016 to 2020
$14.8M
Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7M
Project 3: Epitope Selection in Type 1 DiabetesP01AI118688 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 2016 to 2020
$8.4M
Precision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8M
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6M
NHGRI Genome Sequencing Program Coordinating CenterU24HG008956 · NHGRI · RUTGERS, THE STATE UNIV OF N.J. · PI BUYSKE, STEVEN G, MATISE, TARA C. · 2016 to 2020
$4.9M
Robust and efficient statistical inference methods for genomicsR35GM134922 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI SONG, YUN S · 2020 to 2024
$2.0M
Profiling the Lung Transcriptome for Precision Diagnosis of Respiratory Infections using Host/Pathogen Metagenomic SequencingK23HL138461 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANGELIER, CHARLES · 2018 to 2021
$718k
The Role of RFX6 in Type 1 DiabetesF30DK123915 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAZQUEZ, SARA · 2019 to 2022
$183k
NCATS NIH HHS UL1 TR001866NHGRI NIH HHS U24 HG008956NHGRI NIH HHS UM1 HG006504NHLBI NIH HHS K23 HL138461NHLBI NIH HHS R35 HL140026NIAID NIH HHS P01 AI118688NIAID NIH HHS R01 AI088364NIAID NIH HHS U19 AI077439NIDDK NIH HHS F30 DK123915NIGMS NIH HHS R35 GM134922NIGMS NIH HHS T32 GM007618NIGMS NIH HHS T32 GM067547
6 · The paper itself

Abstract

Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found IFN-I autoantibodies in 19% of critical, 6% of severe and none of the moderate cases. Longitudinal profiling of over 600,000 peripheral blood mononuclear cells using multiplexed single-cell epitope and transcriptome sequencing from 54 COVID-19 patients, 15 non-COVID-19 patients and 11 non-hospitalized healthy controls, revealed a lack of IFN-I stimulated gene (ISG-I) response in myeloid cells from critical cases, including those producing anti-IFN-I autoantibodies. Moreover, surface protein analysis showed an inverse correlation of the inhibitory receptor LAIR-1 with ISG-I expression response early in the disease course. This aberrant ISG-I response in critical patients with and without IFN-I autoantibodies, supports a unifying model for disease pathogenesis involving ISG-I suppression via convergent mechanisms.

Indexed as

autoantibodiesCOVID-19IFNISGperipheral blood mononuclear cellsSARS-CoV2scRNA-seq

Identifiers

PMID33758859
PMCPMC7987018
OpenAlexW3135539232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.